Carmen Gallo Alvarez

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Amadeus Capital Partners Ltd is an independent venture capital firm is founded by Anne Glover and Hermann Hauser in 1997. The firm is headquartered in London, UK.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Seguradoras Unidas SA provides insurance services. Its products include vehicle, health, life, work accidents, multi-risk, civil responsibility, and other insurance. The company is headquartered in Lisbon, Portugal.

Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.

Van Lanschot Kempen NV (Broker) (Van Lanschot Kempen-Broker) is the broker-dealer division of Van Lanschot Kempen NV (AMS: VLK), a financial institution headquartered in Amsterdam, Netherlands. The firm was founded in 1903 and formerly known as Kempen & Co. NV. Van Lanschot Kempen-Broker provides securities broking to institutional investors, companies, financial institutions, (semi) public institutions, foundations and high net-worth individual clients.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.

Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam.

iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA.

Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany.

Medisafe Project Ltd. develops a cloud-synced mobile medication management system. Its platform helps the user manage and take medication on time. The company was founded by Omri Shor and Rotem Shor in 2012 and is headquartered in Matam, Israel.

Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.

IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California.

Biolinq, Inc. develops skin-applied electronic sensors that analyze body fluids to provide health information. The company was founded by Jared Tangney and Josh Windmiller in 2012 and is headquartered in San Diego, CA.

Sonde Health, Inc. develops voice-based technology platform to monitor and diagnose psychological and physical medical conditions. The company was founded by Michael C. Chen and James Harper in 2015 and is headquartered in Boston, MA.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France.

Scipio Bioscience SAS operates as a biotechnology company. It provides a novel sample preparation solution for single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics. The company was founded by Pierre Walrafen and Stuart Edelstein on August 2, 2017 and is headquartered in Paris, France.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.

Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands.

Skywell Capital Partners (Skywell) is a venture capital firm founded in 2014. The firm is headquartered in Tel Aviv, Israel.

Pictor Labs, Inc. engages in technology industry. The company is headquartered in Los Angeles, CA.

NanoSyrinx Ltd is a discovery stage biotechnology company that is based in the UK. The British company is focused on developing protein nanosyringes as a new way to deliver protein and peptide biologic drugs intracellularly. The company uses synthetic biology approaches to achieve this goal. The company was founded by Joseph Healey, Alexia Hapeshi, and Nicholas Waterfield, with Joseph Healey serving as the CEO since incorporation.

EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.